. . . . . . . . . "ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy ninlaro is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy 1" . . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "D/tdjG3PCvVvIEMKgghCIGs+eVHzBK1PNh6voLFxTVFQtdn49tYfKJ+TmNVxreHNiXfqCkNpeBzn5S2WQWZQ6Wvq7RBLXzbBGBitG0y1UDa1XrWGt3xtVcVeVP5cEj8jzWCH11qIr0W/JaI5RaB4Uia32s29avh8Yw6ewaOtlhU=" . . "2021-06-12T12:40:01.858+02:00"^^ . . . . .